Drug Profile

Research programme: nitric oxide-donating therapies - NicOx/Novaliq

Alternative Names: Nitric oxide-donating phosphodiesterase-5 inhibitors - Nicox/Novaliq

Latest Information Update: 27 Oct 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novaliq
Class Antiglaucomas; Eye disorder therapies; Nitro compounds
Mechanism of Action Nitric oxide donors; Type 5 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Oct 2020 Nicox terminates its research and development agreement with Novaliq for nitric oxide donating therapies
23 Oct 2020 Discontinued - Preclinical for Glaucoma in Germany (Ophthalmic)
21 Dec 2018 Novaliq and Nicox agree to develop nitric oxide-donating phosphodiesterase-5 inhibitors for ocular hypertension

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com